Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Viveve Medical Inc (VIVE)
Viveve Medical Inc (VIVE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Viveve to Participate in H.C. Wainwright Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will...

VIVE : 0.0002 (unch)
Viveve CEO Scott Durbin Named Among Top 50 Healthcare Technology Leaders of 2022 by Healthcare Technology Report

Durbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 /...

VIVE : 0.0002 (unch)
Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET today...

VIVE : 0.0002 (unch)
Viveve to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 12, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

VIVE : 0.0002 (unch)
Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update

Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment...

VIVE : 0.0002 (unch)
Viveve to Report Full Year 2021 Financial Results and Provide Corporate Update on March 17, 2022

ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021...

VIVE : 0.0002 (unch)
Healthcare Technology Report Names Viveve Regulatory Executive Among Top 25 Women Leaders in Medical Devices

Viveve SVP Suzon Lommel named to list for second consecutive year for efforts to advance innovative technologies to treat stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / January 13, 2022...

VIVE : 0.0002 (unch)
Viveve to Participate in H.C. Wainwright BIOCONNECT Conference

ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will...

VIVE : 0.0002 (unch)
Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence

Major milestone achieved in Company's advance toward a new U.S. SUI indication ENGLEWOOD, CO / ACCESSWIRE / December 14, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused...

VIVE : 0.0002 (unch)
Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Total revenue of $1.6M reported for Q3 - Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4 ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medical,...

VIVE : 0.0002 (unch)

Barchart Exclusives

Outperforming AMD Stock Still Looks Cheap. Here's Why.
Despite its breakout share price gains, Advanced Micro Devices stock still looks reasonably valued, based on the impressive growth outlooks for artificial intelligence (AI) chips. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar